Samsung Medison, the medical-device subsidiary of Samsung Electronics (005930.KS), has won back-to-back ultrasound supply contracts at two of the most prestigious US hospital systems, Cleveland Clinic and Mayo Clinic, according to Yonhap News Agency (Korea's national wire service), which first reported the deals on June 7. The wins hand the company a foothold in the world's largest medical-device market, where it has long been boxed out by the so-called "GPS" trio of GE, Philips and Siemens.
Under the agreements, a regional hospital under Cleveland Clinic will take Samsung Medison's premium radiology ultrasound system, the "R20," while Mayo Clinic's maternal-fetal medicine (MFM) division will deploy the company's premium obstetrics and gynecology system, the "HERA Z20," per Yonhap. Crucially, Samsung Medison also secured official "preferred supplier" status at Cleveland Clinic, Yonhap reported — a designation that streamlines future purchasing across the system.
Does this move the needle?
That is the first question for any fund manager looking at a single hospital contract: is it material, or just a marquee logo? On revenue, the immediate dollar value of the two deals was not disclosed. But the strategic sizing is clearer. Samsung Medison posted 2025 revenue of ₩665.1 billion ($485 million) and first-quarter 2026 revenue of ₩186.6 billion ($136 million), up 14.1% year over year, according to Seoul Economic Daily. The company's estimated global ultrasound market share rose from 8.4% a year ago to roughly 10.2% in the first quarter of this year, the same outlet reported — evidence that its premium, AI-equipped systems are taking share from the incumbents rather than just discounting into the low end.
The value of these particular hospitals is less about the order size than about who follows. Cleveland Clinic and Mayo Clinic are reference institutions benchmarked by more than 4,000 US hospitals and major centers worldwide, per Yonhap, so a preferred-supplier slot functions as a credential the rest of the market reads.
Why these systems were closed to Samsung before
The R20 carries AI that flags suspected liver and breast lesions and a deep-learning "NerveTrack" feature for nerve and anatomical visualization, while the HERA Z20 automates fetal measurements and 3D placental segmentation, according to Seoul Economic Daily. That software layer is the wedge. Samsung Medison has lifted R&D spending to 17% of revenue in the first quarter of 2026, from 16% in 2024 and 14% in 2023, the outlet reported — a deliberate bet that automation, not price, is how a challenger displaces GE, Philips and Siemens in academic medical centers.
There is a precedent for the playbook working against the GPS trio in their own backyard. In January 2025, Samsung Medison won an ultrasound contract worth about ₩35 billion ($25.5 million) with UniHa, France's largest public-hospital procurement agency — a body under the French health ministry that buys for 1,347 public hospitals, roughly 45% of the country's public facilities — beating GE, Philips and Siemens in competitive bidding, according to Electronic Times (etnews). At the time the company said its AI-based automatic measurement was the deciding factor; the same argument now appears to be landing in the US.
The US build-out behind the deals
The hospital wins arrive months after Samsung Medison reorganized its American presence. On March 23, 2026, the company folded its two US imaging businesses — previously branded NeuroLogica and Boston Imaging — into a single unit, Samsung HME (Healthcare and Medical Equipment) America, spanning ultrasound, digital radiography and CT, according to Imaging Technology News. CEO Kyu Tae Yoo framed the move as reflecting "the growth and maturity of our U.S. medical imaging organization," per the same report. The Cleveland Clinic and Mayo Clinic agreements are the first high-profile validation of that consolidated US structure.
What to watch
The open question is whether these flagship wins convert into a durable shift in Samsung Medison's revenue mix, which has historically leaned on Europe and Asia. The next concrete checkpoint is the company's second-quarter 2026 results and any updated global market-share read: a continued climb above the 10.2% first-quarter figure cited by Seoul Economic Daily would suggest the US premium push is compounding rather than one-off. Until then, the Cleveland Clinic preferred-supplier status is the clearest signal that a Korean challenger has, at minimum, gotten through the door the GPS incumbents have guarded.
This article is for informational purposes only and does not constitute investment advice. Figures are sourced from cited reporting and company disclosures; currency conversions use an approximate rate of 1 USD = 1,370 KRW and are indicative only.
